Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2021 Jan 28;14(4):421–432. doi: 10.1158/1940-6207.CAPR-20-0590

Figure 4.

Figure 4.

Withaferin A (WA) treatment decreases secretion of interleukin-8 (IL-8) in breast cancer cells. A, Quantification of IL-8 secretion in the media of EV and FoxQ1 overexpressing SUM159 and MCF-7 cells after 24 hours of treatment with DMSO or the indicated doses of WA. Results are shown as mean ± SD (n=3). Significantly different (P<0.05) compared with a respective DMSO-treated control or b between EV and FoxQ1 overexpressing cells at the same dose of WA by one-way ANOVA followed by Bonferroni’s multiple comparisons test. B, Rat plasma and tumor levels of IL-8. Statistical significance was analyzed by unpaired Student’s t test. C, Effect of WA treatment on FoxQ1 binding to the IL-8 promoter region (mean ± SD; n=3). *Significantly different (P<0.05) between the indicated groups by one-way ANOVA followed by Bonferroni’s multiple comparisons test. Experiments (A and C) were repeated at least twice with comparable results.